The recent Medtech Conference brought together medical industry professionals from around the world to explore the latest innovations and issues in the sector. This event was an opportunity to discuss decisive themes such as artificial intelligence, diversity in clinical trials and new regulations governing medical devices. Here’s a look at five key learnings that emerge, revealing promising trends and challenges across the medical technology landscape.

The Medtech Conference brought together thousands of professionals to address critical issues in medical technology innovation. Among the key lessons, we find a call to compliance with the new regulations on tests developed in laboratories, a notable stagnation of mergers and acquisitions despite some major transactions, and the importance of diversify inclusion in clinical trials. The growing role of artificial intelligence has raised many questions regarding its regulation. Finally, the importance of listening to patients was highlighted, with a commitment to accessible solutions, particularly for disadvantaged populations. These discussions highlight the need to remain receptive and proactive to the challenges and opportunities of the Medtech industry.

In summary: five key lessons from the medtech conference

The Medtech Conference, held in Toronto, brought together thousands of professionals from around the globe to discuss the future of medical technology. Among the many topics covered, the role of artificial intelligence and the machine learning captivated the attention of the participants. The discussions highlighted the growing importance of these technologies in medical device development, and how they can help improve patient outcomes while optimizing costs. Additionally, leaders like Acting FDA Director Michelle Tarver have emphasized the importance of listening to patients to shape industry practices and regulations.

A need for alignment with regulatory standards

Experts discussed the critical need to comply with recent regulatory changes regarding laboratory developed tests (LDT). The new regulation, which is planned to be implemented from 2025, imposes strict requirements in terms of reporting and quality. Laboratories must prepare for these changes to avoid being caught off guard. According to Scott Garrett, compliance experts suggest staying constantly informed of regulatory developments so as not to become the “model” of what not to do in terms of compliance, thus putting companies in a delicate position vis-à-vis FDA requirements.

Importance of diversity in clinical trials

Another central point discussed at the conference was the importance of diversity in clinical trials. Organizers introduced new guidelines aimed at increasing the inclusion of underrepresented populations in clinical trials. This initiative aims to ensure that medical products meet the needs of a broader patient base, thereby leading to improved outcomes for all. At the same time, professionals have highlighted the need to integrate patient feedback to better guide the development of devices, which could transform the way trials are designed and conducted in the future.